Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures dips below year-ago levels
Q2 FY2026 capital expenditures of $112.2M (cash outflow) fell 23.0% year over year, behind the +43.3% change in trailing-twelve-month capital expenditures. Sequentially, it fell 15.9% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.
Context
- Capital expenditures amounted to 3.6% of revenue in FY2025, up 0.9 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -23.0% toward the trailing-twelve-month pace of +43.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (437.6M) USD
- Year-over-year change
- -47.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (437.6M) | -47.0% |
| FY2024 | 2024-12-31 | (297.7M) | -15.2% |
| FY2023 | 2023-12-31 | (258.4M) | -26.2% |
| FY2022 | 2022-12-31 | (204.7M) | +12.9% |
| FY2021 | 2021-12-31 | (235M) | — |
Capital Expenditures vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Jun 2026 capital expenditures of $496.8M is the 2nd largest of the 11 companies compared; the peer median is $41.27M.
- Its year-over-year change of +43.3% is the 6th highest of 11, against a peer median of +84.7%.
- Capital expenditures amounts to 3.9% of revenue for VRTX, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $78.07B | +88701.7% | -5.2% | 7.6% | |
| LTM Jun 2026 | $496.8M | +43.3% | +28.8% | 3.9% | |
| LTM Jun 2026 | $302.05M | +1172.9% | +25.3% | 29.9% | |
| LTM Jun 2026 | $91.95M | +151.6% | -6.6% | 1.9% | |
| LTM Sep 2026 | $71.85M | +29.1% | +36.8% | 7.5% | |
| LTM Mar 2026 | $69.14M | -54.0% | +46.8% | 3.2% | |
| LTM Jun 2026 | $13.39M | +24.6% | -32.7% | 8.6% | |
| LTM Mar 2026 | $9.32M | +140.4% | -65.5% | 1.4% | |
| LTM Jun 2026 | $5.52M | -52.7% | -44.2% | 0.8% | |
| LTM Sep 2026 | $2.08M | +220.0% | -70.9% | 8.3% | |
| LTM Mar 2026 | $473K | -88.2% | -53.7% | 0.7% | |
| Peer median (excluding VRTX) | $41.27M | +84.7% | -19.6% | 5.3% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| Deferred Income Tax | (154.6M) | (275.9M) | (536.5M) | (348.8M) | (510.8M) |
| Stock-Based Compensation | 441.4M | 491.3M | 581.2M | 698.5M | 685.9M |
| Change in Working Capital | (105.2M) | 340.8M | (265.7M) | (514.8M) | (1.2B) |
| Accounts Receivables | (274.7M) | (358.6M) | (84.1M) | (99.3M) | (347.3M) |
| Inventory | (92.8M) | (136.4M) | (322.9M) | (517.3M) | (524.2M) |
| Accounts Payables | 31.9M | 120.8M | 48.7M | 49.5M | 36.8M |
| Other Working Capital | 230.4M | 715M | 92.6M | 52.3M | (364.4M) |
| Other Non-Cash Items | (5.8M) | 103.4M | (42.6M) | 900K | 492.4M |
| Operating Cash Flow | 2.64B | 4.13B | 3.54B | (492.6M) | 3.63B |
| Capital Expenditures | (235M) | (204.7M) | (258.4M) | (297.7M) | (437.6M) |
| Acquisitions (Net) | 77M | (295.9M) | 0 | 0 | 0 |
| Purchases of Investments | (605.2M) | (692.7M) | (3.79B) | (7.7B) | (6.4B) |
| Sales of Investments | 499.3M | 920M | 934.2M | 4.47B | 5.91B |
| Other Investing Activities | (77M) | (47.8M) | (89M) | (241.7M) | (24.7M) |
| Investing Cash Flow | (340.9M) | (321.1M) | (3.14B) | (3.77B) | (945.4M) |
| Debt Repayment | (18.7M) | (85.5M) | (44.9M) | (33.6M) | (5.4M) |
| Common Stock Issued | 102M | 186.3M | 134.6M | 114.6M | 127.7M |
| Common Stock Repurchased | (1.43B) | (172M) | (427.6M) | (1.18B) | (2.02B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (130.2M) | 3.5M | (224.3M) | (398.8M) | (366.2M) |
| Financing Cash Flow | (1.48B) | (67.7M) | (562.2M) | (1.49B) | (2.26B) |
| Effect of Forex Changes | (13.4M) | (29.2M) | 26.9M | (42.6M) | 90.9M |
| Net Change in Cash | 811.2M | 3.71B | (139.7M) | (5.8B) | 515.6M |
| Free Cash Flow | 2.41B | 3.93B | 3.28B | (790.3M) | 3.19B |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.